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Neuroblastoma is a childhood tumour of the peripheral sympathetic
nervous system. The pathogenesis has for a long time been quite
enigmatic, as only very few gene defects were identified in this often
lethal tumour1. Frequently detected gene alterations are limited to
MYCN amplification (20%) and ALK activations (7%)2–5. Here we
present a whole-genome sequence analysis of 87 neuroblastoma of
all stages. Few recurrent amino-acid-changing mutations were
found. In contrast, analysis of structural defects identified a local
shredding of chromosomes, known as chromothripsis, in 18% of
high-stage neuroblastoma6. These tumours are associated with a
poor outcome. Structural alterations recurrently affected ODZ3,
PTPRD and CSMD1, which are involved in neuronal growth cone
stabilization7–9. In addition, ATRX, TIAM1 and a series of regula-
tors of the Rac/Rho pathway were mutated, further implicating
defects in neuritogenesis in neuroblastoma. Most tumours with
defects in these genes were aggressive high-stage neuroblastomas,
but did not carry MYCN amplifications. The genomic landscape of
neuroblastoma therefore reveals two novel molecular defects, chro-
mothripsis and neuritogenesis gene alterations, which frequently
occur in high-risk tumours.
Neuroblastoma have a highly variable clinical outcome, with an
excellent prognosis for stage 1 and 2 tumours, but a poor outcome
for high-stage tumours. Stage 4S neuroblastoma are metastasized but
nevertheless undergo spontaneous regression. Low-stage tumours are
marked by numeric changes of chromosomal copy numbers, whereas
high-stage tumours typically show structural chromosomal defects
resulting in, for example, hemizygous deletions of the chromosomal
regions 1p36 or 11q and gain of 17q (refs 1, 10–12). Age at diagnosis
above 1.5 year is associatedwithhigh-stage tumours andpoor outcome.
We performed whole-genome paired-end sequencing as used by
Complete Genomics13 for 87 untreated primary neuroblastoma
tumours of all stages (Supplementary Table 1) and their corresponding
lymphocyte DNAs. All samples had aminimal tumour content of 80%
as determined by immunohistochemical analysis. Genomes were
sequenced at an average coverage of 50 and an average fully called
genome fraction of 96.6% (Supplementary Table 2). Compared to the
HG18 reference genome we obtained an average of 3,347,592 single-
nucleotide variants (SNVs) per genome, in accordance with reported
frequencies of interpersonal variants. CGAtools was used to compare
tumour with lymphocyte genomes and provided a somatic score
estimating the likelihood of mutations to be somatic (http://cgatools.
sourceforge.net/docs/1.3.0/). Validation of 1,014 candidate somatic
small mutations (SNVs, substitutions, insertions, deletions), including
763 SNVs, established a specificity of 88% and a sensitivity of 85% at a
somatic score cut-off of 0.1 (Supplementary Fig. 1a). SNVs above this
score and all validated SNVs with lower scores were used for further
analyses (total 586 genes, Supplementary Table 3). The sequence data
identified an average of 12 somatic candidate amino-acid-affecting
mutations per tumour (Fig. 1a and Supplementary Fig. 1b). The fre-
quency of somatic events strongly correlated to tumour stage where
stage 1, 2 and 4S tumours have very fewmutations compared to stage 3
and 4 tumours (analysis of variance (ANOVA) P5 7.63 1026;
Fig. 1b). In addition mutation frequencies were strongly correlated
to overall survival (log-rankP5 9.83 1027; Fig. 1c) and age at diagnosis
(r5 0.53, P5 1.13 1027; Fig. 1d), as was also observed in medul-
loblastoma14. Within high-stage neuroblastoma,MYCN amplification
status didnot correlate tomutation frequency (SupplementaryFig. 1c).
Only very few recurrent mutations were identified. ALK mutations
were found in 6% of the tumours, in accordance with frequencies estab-
lished in largeneuroblastoma tumour series (SupplementaryTable 4)2–5.
Three tumours carried mutations in TIAM1, a known regulator of
cytoskeleton organization and neuritogenesis15. In a parallel study we
sequenced four primary neuroblastoma tumours as well as cell lines
derived from these tumours and their metastases. This revealed that
primary tumours are already heterogeneous for mutations and that
the large majority of them were passenger or late mutations (J.J.M.
et al., submitted). Together with the lack of recurrent mutations, our
data indicate that neuroblastoma carry few early somatic tumour-
driving mutations with amino-acid-changing consequences.
Analysis of the paired-end clones with discordant ends can be used
to identify candidate structural rearrangements, which together with
sequence coverage data can identify somatic structural variants (SVs).
Comparison of tumour versus lymphocyte coverage generated ultra-
high-resolution comparative genomic hybridization (CGH)-like profiles
(Supplementary Fig. 2a). Analysis of the frequency of structural varia-
tions per chromosome revealed ten tumours with chromothripsis
characteristics6 (seeMethods). Chromothripsis is a localized shredding
of a chromosomal region and subsequent random reassembly of the
fragments. An extreme example of chromothripsis in chromosome 5 is
shown in Fig. 2a and 2b (for other cases see Supplementary Fig. 2b).
The neuroblastoma with chromothripsis were associated with a poor
prognosis (log-rank test P5 7.13 1023; Fig. 2c). They were found
in 18% of the stage 3 and 4 neuroblastoma, but not in low-stage
tumours (Fisher’s exact test P5 0.01). Accordingly, their prognostic
impact is not independent of age and stage in multivariate analyses.
Chromothripsis-related structural aberrations frequently affected
genes involved in neuroblastoma pathogenesis and were associated
with amplification of MYCN or CDK4 and loss of heterozygosity of
1p (Supplementary Fig. 2c). In one tumour, chromothripsis resulted in
amplification and very strong overexpression of MYC (c-Myc) (Sup-
plementary Fig. 2d). Chromosome 5 had undergone chromothripsis in
three tumours, but no clear tumorigenic target on this chromosome
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was identified. To identify genetic defects that allowed chromothripsis
and subsequent survival of the cell, we searched for defects in DNA
damage response pathways in tumours with chromothripsis. Themost
extreme case of chromothripsis (N492, Fig. 2a and 2b) showed an
inactivating deletion in FANCM and another chromothripsis tumour
sample (N576) had a missense mutation in FAN1, predicted to be
damaging by the polyphen2 program16. These findings might suggest
involvement of inactivating events in the Fanconi anaemia signalling
pathway to allow chromothripsis17.
Full genome paired-end sequencing allowed us to identify structural
variants specifically perturbing single genes (see Methods and Sup-
plementary Fig. 4 for selection procedure). We detected a total of 451
genes harbouring structural variants (306 genes without the events on
chromothripsis chromosomes, Supplementary Tables 5 and 6). The
structural variants often consisted of deletions of one or a few exons,
inversions or translocations deletingpart of a gene.One tumour showed
an intrachromosomal rearrangement activating FOXR1 transcription
(SupplementaryFig. 2e), whichwe recently identified as a recurrent but
rare event in neuroblastoma18. Similar to the findings for amino-
acid-changing mutations, there was a strong relation between the fre-
quency of structural variations and the tumour stage (one-way
ANOVA P5 0.03; Fig. 1e), which extends the well-established rela-
tionship between tumour stage and structural chromosomal defects in
neuroblastoma10–12. Breakpoints identifying deletions were supported
by changes in coverage plots. Most of the structural variants affected
only one allele of a gene (Supplementary Table 5). This indicates that
the tumour-driving mechanism of these defects is haploinsufficiency,
possibly combined with epigenetic attenuation of the non-affected
allele. On average, genes with structural variants resulting in loss of
coverage indeed showed a reduced expression in tumours with these
defects, as compared to tumours with normal alleles (Supplementary
Fig. 2f). As an additional validation, we generated SNP arrays of 52 of
the sequenced tumours. Although the SNP data have a much lower
resolution than the sequence coverage plots, they supported the dele-
tions and gains of sufficient size. This is especially evident on plots of
chromothripsis samples (Supplementary Fig. 2g).
To identify relevant genes and pathways that contribute to neuro-
blastoma pathogenesis, we generated one list of all genes with amino-
acid changing mutations (n5 586), mutations in splice junctions
(n5 37) and structural variations (n5 451). The total of 1,041 genes
with alterations were analysed by two approaches. First, we analysed
the most frequently affected genes (Supplementary Table 7). Four
genes belonged to the MYCN amplicons (MYCN, MYCNOS, DDX1
andNBAS) and except forMYCNprobablyplaynorole inpathogenesis.
Three genes, PTPRD, ODZ3 and ATRX, showed structural variants in
five tumours each (Fig. 3a and Supplementary Fig. 3a) and 61 genes
showed alterations in two to four tumours (Supplementary Table 7). A
conservative randomization, taking the length of all genes and the
structure of our data set into account, showed that the chance of
finding three genes affected in five or more tumours is,2.113 1024
(see Methods). This strongly indicates that at least the defects in
PTPRD, ATRX and ODZ3 did not accumulate due to for example,
the genomic length of the genes, but that they were selected for during
the process of tumorigenesis.
The X-chromosome-encoded ATRX gene was affected by structural
variants in five tumours (Fig. 3a). In two male patients this resulted in
complete inactivation of the gene. FrequentATRXdefects were recently
found in pancreatic neuroendocrine tumours19. ATRX is a chromatin
remodelling protein involved in exchange of H3.3 in GC-rich repeats
andmutations of this gene are associatedwithX-linkedmental retarda-
tion20. ExonmRNAprofiles of part of the sequenced series showed that
the three samples included with ATRX structural variations had the
lowest ATRX mRNA expression of all samples and showed a specific
collapse of the signal in the deleted regions, illustrating the inactivating
nature of the ATRX defects (Fig. 3b and Supplementary Fig. 3b).
ODZ3 and PTPRD were also hit by structural variations in five
tumours each (Supplementary Fig. 3a). One tumour showed homo-
zygous inactivation of ODZ3 (see legends of Supplementary Fig. 3a).
In addition, ODZ2 and ODZ4, two highly homologous members of
the conservedODZ family, were together affected three times. PTPRD
and ODZ genes encode transmembrane receptors expressed in the
developing nervous system and localizing to axons and axonal growth
cones21. Targeted silencing of ODZ homologues in Drosophila,
Caenorhabditis elegans and mouse caused severe axon guidance
defects9. Overexpression of ODZ2 in neuroblastoma cells enhanced
neuritogenesis22. PTPRD is amember of the LAR subfamily of receptor
protein tyrosine phosphatases. Transgenic mouse models strongly
implicate the LAR subfamily receptors in neuritogenesis8. PTPRD
defects in neuroblastoma were reported previously23. Low expression
of ODZ3 and of PTPRD as assessed by mRNA profiling were
both associated with a poor prognosis (log-rank P5 3.13 1024 and
P5 5.73 1023, respectively; Supplementary Fig. 3a). Interestingly,
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Figure 1 | Frequency of amino-acid-changing somatic mutations in
neuroblastoma correlates with age, stage and survival. a, The number of
amino-acid-changing mutations in 87 primary neuroblastoma (single
nucleotide variants (SNVs) in red, deletions in grey, insertions in green and
substitutions affecting more than 1 base pair (Sub) in blue). Numbers shown
are events after CGAtools CallDiff with somatic scores.0.1 and not present in
dbSNP130, nor in 46 reference genomes released by Complete Genomics.
b, Average number of mutations per tumour stage (International
Neuroblastoma Staging System (INSS) stage 1, n5 9; stage 2, n5 14; stage 3,
n5 5; stage 4, n5 50 and stage 4S, n5 9). Boxes include 50% of data and error
bars indicate extremes with a maximum of two times the box size. st., stage.
c, Kaplan–Meier curves for tumours with high versus low frequency of
mutations. The optimal cut-off level for the categories was determined by
Kaplan scanning (see Supplementary Information and Methods). The
significance (log-rank test) was corrected for the multiple testing (Bonferroni
correction). Number of patients per group is shown in parentheses. d, Age at
diagnosis (rank-order) versus the number of somatic variants. e, Average
number of structural variations per tumour stage (INSS). Group sizes and the
definition of the error bars as in Fig. 1b.
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CSMD1, which showed structural variants in three tumours, is also a
transmembrane protein expressed on nerve growth cones7. As the
frequencies of PTPRD andODZ3 defects exclude that they were found
by chance, we propose that the function of these genes and of ODZ2,
ODZ4 andCSMD1 in neuronal growth conesmight hold a clue to their
function in neuroblastoma pathogenesis.
The second analysis that we performed for the list for 1,041 affected
genes was a gene ontology study to identify enrichment of genes with
defects in specific molecular processes. The gene ontology category
‘regulation of GTPase activity’ was the most significantly enriched
group (Bonferroni corrected for multiple testing: P5 6.73 1024; see
supplementary methods and Supplementary Table 9). This finding
urged us to further investigate GTPase-regulating genes in the list.
TIAM1 was mutated in three tumours (see Supplementary Table 4).
It functions as a guanine nucleotide exchange factor (GEF) for the
small GTPase Rac and is, together with Rac, central to regulation of
cellular polarity and neuritogenesis24,25. The W1285S* mutation
creates a premature stop-codon in the carboxy-terminal pleckstrin
homology domain required for Rac activation, whereas the other
mutations were predicted to be damaging by polyphen2 analysis16.
Rac is activated byGEFs and inactivated byGTPase activating proteins
(GAPs)26 (Fig. 4). We identified a total of eight alterations in six GEFs
specific for Rac (including TIAM1), but none in GAPs specific for Rac
(Supplementary Tables 7, 8 and 10 for functional consequences).
Whereas activation of Rac1 stimulates neuritogenesis, activation of
its small GTPase antagonist RhoA promotes axon retraction and
growth cone collapse (Fig. 4a)15. Strikingly, we detected seven altera-
tions in five GAPs for RhoA, but only one GEF specific for RhoA
(ARHGEF12) showed a translocation with unknown functional con-
sequences (Fig. 4a, Supplementary Tables 7, 8 and 10 for functional
consequences). The bias for inactivation ofGAPs forRho andGEFs for
Rac is highly significant (one-sided Fischer’s exact test: P, 0.0007).
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Figure 3 | Structural variations in ATRX result in low mRNA expression
levels. a, Coverage plots displaying the structural variations in the ATRX gene.
The dots indicate summed coverage for bins of 1,000 base pairs of the tumour
genome, normalized to the coverage in corresponding normal tissue. The
intron-exon structure of ATRX is shown in red (dark red are exons). b, ATRX
mRNA expression of 70 tumours as measured on Affymetrix full-exon arrays.
Tumours with ATRX deletions are encircled. Coloured tracks below figure,
from top to bottom: age at diagnosis (green, 1.5 year, red. 1.5 year); survival
(red, dead; dark green, alive.5 year; light green, alive,2 year); MYCN
amplification (red, yes; green, no); stage (light green, stage 1; dark green, stage 2;
brown, stage 3; red, stage 4; blue, stage 4S).
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Figure 2 | Chromothripsis is frequent in neuroblastoma and is associated
with a poor prognosis. a, Circos plot showing structural variations in sample
N492. The inner ring represents the copy number variations (red, gain; green,
loss) based on coverage of the tumour and lymphocyte genomes. The lines
traversing the ring indicate inter- and intrachromosomal rearrangements
identified by discordant mate pairs from paired-end reads. N492 is a
chromothripsis sample with an extreme amount of junctions on chromosome
5.b, Circos plot of the affected chromosome5 in sampleN492. c, Kaplan–Meier
curves of the overall survival for tumours with or without chromothripsis.
Numbers of patients per group are shown between brackets.
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This indicates that alterations in GTPase-regulating genes specifically
function to activate Rho or inactivate Rac, which both tip the balance
in Rac/Rho signalling towards inhibition of neuritogenesis. Of note,
transgenic mice with ATRX mutations causing mental retardation in
humans showed abnormal dendritic spine formation with increased
TIAM1 phosphorylation and Rac1 signalling27.
We conclude that alterations with significant frequencies (PTPRD
and ODZ genes) affect transmembrane receptors that function in
neuronal growth cone guidance and maintenance. In addition gene
ontology analysis of the 1,041 genes showed significant enrichment of
GTPase-regulating genes. Alterations in GEFs for Rac and GAPs for
Rho significantly deviate from a random distribution, implicating
inhibition of Rac1 and activation of RhoA in impairing neuritogenesis
in neuroblastoma (Fig. 4a).
From these findings we propose that defects in neuritogenesis-
regulating genes form an important category of tumour-driving events
in neuroblastoma. For a preliminary analysis of tumours with these
defects, we selected the genes with recurrent defects in tumours that
function in neuronal growth cones (PTPRD,ODZ3,ODZ2,CSMD1) or
regulation of these processes through Rac/Rho signalling (TIAM1,
DLC1, ARHGAP10, ATRX). The 19 tumours with defects in these
genes were almost all stage 3 and 4 tumours diagnosed above 1.5 year
of age with an aggressive clinical course. Only few of them showed
amplification ofMYCN (Fig. 4b). Consistent with their occurrence in
high-stage neuroblastoma, defects in neuritogenesis genes did not
show an independent prognostic power in multivariate analysis with
the clinical parameters age and stage.
Here we report the first whole-genome sequence study of a com-
prehensive series of neuroblastoma including both low- andhigh-stage
tumours. Low-stage neuroblastoma lacked recurrent gene alterations
(mutations and structural variations), raising the question whether
they are primarily driven by chromosomal imbalances and the con-
sequent gene dosage effects. Tumours with defects in genes function-
ing in neuritogenesis or growth cone guidance mostly are aggressive
high-stage tumours withoutMYCN amplification. Interestingly, there
is indication thatMYCNalso inhibits neuritogenesis in neuroblastoma.
MYCN downregulates themRNA expression of the chromosome 1p36
gene CDC42, which resulted in inhibition of neuritogenesis of neuro-
blastoma cells28. CDC42 is a small GTPase protein with a function
similar to Rac1. Rac1 andCDC42 both regulate the Par3–Par6 complex
(also known as PARD3–PARD6A) involved in cell polarization and
growth cone development and which has been shown to drive neuro-
blastoma cell differentiation25. In light of our data demonstrating geno-
mic alterations in Rho/Rac signalling, it is tempting to postulate that
the Par3–Par6 complex is a recurrent target for inactivation in neuro-
blastoma. Intriguingly, the block in neuritogenesis of neuroblastoma is
probably not absolute. Retinoic acid can induce neuronal outgrowth in
many neuroblastoma cell lines, which all are derived from high-stage
tumours. Retinoic acid is also used in long-term neuroblastoma treat-
ment protocols toprevent recurrences29. It is currentlyunknownwhich
tumours will clinically respond to retinoic acid therapy. Deletions of
NF1 were previously implicated in retinoic acid resistance of neuro-
blastoma cell lines30. The identification of genomic alterations in a
range of genes mediating neuritogenesis now allows investigation of
therapeutic modalities to surmount these defects.
METHODS SUMMARY
All neuroblastoma samples were derived from primary tumours of untreated
patients. Tumour material was obtained during surgery and a portion was imme-
diately frozen in liquid nitrogen. We used leukocytes derived from peripheral
blood for isolation of constitutional DNA. High-molecular-weight DNA was
extracted from tumour tissue and leukocytes using standard procedures. Fifteen
microgram of DNA was subjected to paired-end whole-genome sequencing
according to the Complete Genomics technology. Initial data analyses were per-
formed using the CGAtools v1.3.0 package (http://cgatools.sourceforge.net/docs/
1.3.0/) and for subsequent analysis and figure preparation we used the R2
bioinformatic platform (http://r2.amc.nl) andPERL scripts.More details onmuta-
tion analysis, coverage analysis, analysis of structural variants and the Circos plots
is given in the Supplementary Information. Gene expression was assayed on
Affymetrix EXON ST 1.0 GeneChips. SNP genotypingmicroarray analysis details
are described in the supplementary information. Mutation validations were per-
formedusing Sanger sequencing (Supplementary Information). Statistical analysis
(gene ontology enrichment using the Cytoscape BINGO plugin, DAVID func-
tional ontology cluster analysis and analysis for gene length enrichment) are
described in the Methods.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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METHODS
Small variants. Variant selection procedure: Potential somatic variants were
determined with the CallDiff method with somatic output within the CGAtools
v1.3.0 package, maintained by Complete Genomics (http://cgatools.sourceforge.
net/docs/1.3.0/). Every tumour or cell line sample was compared to its matched
blood sample across thewhole genome. The somatic score which is calculated tries
to tease apart true somatic mutations from false somatic mutations (http://
cgatools.sourceforge.net/docs/1.3.0/). The somatic output files were then filtered
to those regionswhere coding sequences are defined for theUCSC refflat annotation
(http://hgdownload.cse.ucsc.edu/goldenPath/hg18/database/refFlat.txt 2 August
2010), thereby removing discontinued genes from the original annotation of
NCBI36.3. Subsequently, gene symbol, amino acid change and effect categories
were extracted from gene-GSXXX-ASM.tsv files for all genomes and added as
annotation to the somatic output results. Those variants that could not be
annotated (new/updated genes) were annotated with custom PERL scripts where
possible. All variants were annotated for their presence in dbSNP130 (http://
hgdownload.cse.ucsc.edu/goldenPath/hg18/database/snp130.txt), as well as the
presence within 37 public HapMap genomes released by complete genomics
(ftp://ftp2.completegenomics.com/). SIFT (http://sift.jcvi.org/www/SIFT_chr_coords_
submit.html NCBI36) and polyphen2 (http://genetics.bwh.harvard.edu/pph2/
bgi.shtml NCBI36) scores were determined to assess potential impact for all the
SNPvariants.Variants, which are reported in dbSNP130, that were found in any of
the normal blood samples or that were found within the public genomes from
Complete Genomics were removed from the data set. Finally, variants which were
found in genes that are not expressed in neuroblastoma, but do show expression in
a series of 500 normal sampleswere removed (SeeAffymetrix expression analysis).
Somatic small variants trim-down. CallDiff with somatic output was performed
on all of the 87 tumour/lymphocyte pairs and processed. The number of events
(split by deletion/insertion/substitution/SNP) were counted for the complete
genome. Next, the somatic output files were filtered on those parts of the genome
that are covered by amino-acid-encoding regions(based on the coding sequence
(CDS) within the refflat file from the UCSC). In the next step, only those variants
were kept that have an impact on the coding sequence (non-silent), do not occur in
any of our normal samples, nor in any of the publicly available genomes from
Complete Genomics, nor are present in dbSNP130. Finally, we filtered for the
somatic score to be $0.1 (as determined by plotting of the Sanger sequence
validation results as a function of somatic scores and total scores).
Sanger sequencing. High-molecular-weight DNA was extracted from tumour
tissue and leukocytes using standard procedures31. Primers for PCR amplification
were automatically designed by custom PERL scripts that execute the Primer3
software. PCR was performed using 20 ng of genomic DNA. Sanger sequencing
was performed on a capillary sequencer using standard procedures.
CompleteGenomics comparative genomic hybridization (cgCGH) procedure.
First we determine the summed coverage (uniqueSequenceCoverage) in windows
of 1,000 base pairs (measured on the reference genome) for the normal and the
tumour sample (coverageRefScore files). Here we take the Integer(position/1,000)
as the bin for any position and keep track of the sum. Then we determine the total
coverage sums of the genome and normalize to this value, to remove differences in
total coverage between samples. Subsequently we determine the log(tumour/
genome)/log(2) for every bin (1,000-bp window) and obtain a cgCGH profile that
expresses the somatic changes of the respective tumour. As the profile is normalized
to its ownnormalmaterial, themost prominent sources of bias such asGC-content,
and also per-person copy number variation characteristics are corrected for. We
feed these results to the DNAcopy algorithm as provided in R BioConductor to
segment the information into blocks of similar characteristics and use these seg-
ments boundaries to store the information in an efficient way. cgCGH data was
visualized within the embedded genome browser of R2 (http://r2.amc.nl).
Circos plots. Comparisons of somatic structural variants between tumour and
lymphocyte genomes were performed with the JunctionDiff and Junction2Event
tool from CGAtools (http://cgatools.sourceforge.net/docs/1.4.0/). These somatic
events were filtered with the following criteria: events annotated as artefacts,
footprints smaller than 70 bases, less than 10 discordant mate pairs, under-
represented repeats, and presence in a set of v2.0 baseline genomes (as provided
at the website of Complete Genomics (B36baseline-junctions.tsv)). cgCGH pro-
files and the remaining events were plotted with the Circos program (http://
www.circos.ca).
Chromothripsis. Genomes were annotated as having chromothripsis-like char-
acteristics when the sum of intra-chromosomal somatic junctions (as reported by
JunctionDiff and filtered as above) within a single chromosomewas larger or equal
to 20. Focused amplified regions (cgCGH scores$3) within a chromosome were
excluded from this sum. Using these characteristics, we annotated 10 out of the 87
patients as chromothripsis-like. Nine out of these patients were diagnosed with
stage 4 neuroblastoma (P5 0.0392 stage4 versus rest) and all 10 were present in
high-stage neuroblastoma (P5 0.0116). Eight of these patient have died of the
disease (P5 0.0413; log-rank P5 7.13 1023).
Affymetrix expression analysis (expressed genes). To assess whether genes con-
taining variants are expressed in neuroblastoma, wemake use of a panel of neuro-
blastoma tumours (also including 53 of the sequenced tumours), classical
neuroblastoma cell lines as well as recently generated patient derived cell lines
(n5 119 in total).All samples were derived from primary tumours of untreated
patients. Material was obtained during surgery and immediately frozen in liquid
nitrogen. The original sources for classical neuroblastomacell lines can be found in
ref. 32. Total RNA of neuroblastoma samples was extracted using TRIzol reagent
(Invitrogen) according to the manufacturer’s protocol. RNA concentration and
quality were determined using the RNA 6000 nano assay on the Agilent 2100
Bioanalyzer (Agilent Technologies). Fragmentation of complementary RNA,
hybridization to hg-u133 plus 2.0 microarrays and scanning were carried out
according to the manufacturers protocol (Affymetrix). The data were deposited
in the NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/)
under accession number GSE16476.
Affymetrix expression data from adult tumours were derived from the
Expression Project for Oncology (ExpO) database from the International
Genomics Consortium (IGC) (http://www.intgen.org/expo.cfm). Expression data
on normal tissues was downloaded from GEO (GSE7307). The expression data
were normalized with the MAS5.0 algorithm within the GCOS program of
Affymetrix. Target intensity was set to 100. If more than one probe set was
available for one gene the probe set with the highest expression was selected,
considered that the probe set was correctly located on the gene of interest. For
101 patients (60 of the sequenced tumours), we have also generated Affymetrix
Exon array data. The z-score of expression within this data set was used as a
independent validation of structural variants annotated as deletions, where
possible. All data were analysed using our in-house-developedR2web application,
which is freely accessible at http://r2.amc.nl.
SNP array analysis. SNP arrays were processed according to the manufacturer’s
recommendations with the Infinium II assay on Human370- and Human660-
quad arrays containing.370.000 and.660,000markers, respectively, and run on
the Illumina BeadStation (Swegene Centre for Integrative Biology, Lund
University — SCIBLU, Sweden) according to the manufacturer’s recommenda-
tions. Raw data were processed using Illumina’s BeadStudio software suite
(Genotyping module 3.0), producing report files containing normalized intensity
data and SNP genotypes. Subsequently, log2 ratio and B-allele frequency data were
imported into the R2 web application for detailed analysis and comparison with
the CGH and expression data.
Selection procedure somatic small variants table.We ran CallDiff with somatic
output on all of the 87 tumour/lymphocyte pairs and processed the somatic output
files as described in the small variants section earlier. Due to the low validation
percentages of substitutions and insertions, these were removed from the table.
Variants which were tested by Sanger sequencing and were all-reference or all-
variant were removed from the table. Variants with somatic scores lower than 0.1
or of types insertion/substitution, but which were validated by Sanger sequencing,
were maintained in the table. In addition, we determined the presence of somatic
splice-site variants in the two bases surrounding exons as defined by the UCSC
refflat data.
Selection procedure somatic structural variant table. Comparisons between
tumour and lymphocyte genomes were performed with the JunctionDiff and
Junction2Event tool from CGAtools. These somatic events were filtered with
the following criteria: events annotated as artefacts, footprints smaller than 70
bases, less than 10 discordant mate pairs, under-represented repeats, and presence
in a set of baseline genomes (as provided at the website of Complete Genomics
(B36baseline-junctions.tsv)). Of the remaining entries, we kept the following
events: exon_bites where both ends of a junction are within the same gene, and
in addition affect exonic sequence. Breaks by inversion, where both ends of a
junction land within a gene, thereby damaging both genes, but leaving the genes
in between unaffected. Potential fusion genes which are strand-matched, where
both ends of a junction land within a gene, and the resulting end product fits in
terms of orientation of both genes. Regions (deletions/(tandem) duplications) of up
to 1 megabase, containing up to five genes which are expressed in neuroblastoma.
Combination of small, splice and structural somatic variants table. The small
variant, structural variant and splice-site somatic tables were merged on the gene
symbol, and unique tumour IDs were counted to obtain a final list of recurrent
gene affecting variants.
Kaplan scan. Kaplan scanning was performed within R2 (http://r2.amc.nl). In
short, for each gene or other numerical characteristic, R2 calculates the optimal
cut-off expression level dividing the patients in a good and bad prognosis cohort.
Samples within a data set are sorted according to the expression of the investigated
gene and divided into two groups on the basis of a cut-off expression value. All
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cut-off expression levels and their resulting groups are analysed for survival, with
the provision that minimal group number is 8 (or any other user-defined value)
samples. For each cut-off level and grouping, the log-rank (as described in ref. 33)
significance of the projected survival is calculated. The best P value and corres-
ponding cut-off value is selected. This cut-off level is reported and used to generate
a Kaplan–Meier graph. The graph depicts the log-rank significance (‘raw P’), as
well as a P value corrected for the multiple testing (Bonferroni correction) of cut-
off levels for each gene.
Statistical analysis for gene ontology gene enrichment. To investigate the pos-
sible role of the mutated genes we used the BinGO plugin34 for the network
visualization tool Cytoscape35. This tool assesses enrichment of gene ontology
categories for a set of genes. The P-value assigned to the overrepresentation for
a specific category is calculated through a hypergeometric test. Results are cor-
rected for multiple testing. We used the set of 1,041 genes having a mutation or
structural variation in one or more neuroblastoma tumours. In the more inform-
ative gene ontology categories (filter set to less than 500 genes per category); the
‘regulation of GTPase activity’ gene ontology category seemed to be the most
significant. The DAVID online functional clustering tool36 confirmed this analysis
for the biological process gene ontology branch; the third cluster in the list con-
tained the GTPase regulation category with an enrichment score of 1.44.
Statistical significance of genes affected by amino-acid-changing mutations
and structural variations. We analysed the likelihood of finding defects in
specific genes, or of finding defects in equal to/more than the number of
affected patients. We therefore used the following randomization strategy: we
started by counting the number of genes affected by structural variations, for every
sample in our data set. Next, the genomic footprints (bases from start to the end of
the RefSeq on the HG18 genome (UCSC refflat August 2010)) were determined
and merged to the largest possible span for every gene symbol. These stretches
were fused to create an artificial sequence, with the length of all gene symbols
combined. Within this artificial sequence, random nucleotide numbers were
chosen and traced back to the corresponding gene symbols. This was done for
each tumour sample separately, with the number of randomly selected nucleotides
being identical to the number of structural defects identified in the actual
(sequenced) tumour. An identical strategy was used for the CDS affecting
amino-acid-changing mutations, where the length of the largest CDS (NCBI
RefSeq data set August 2010) per gene symbol has been used, to generate the
artificial sequence.
In this way, we could generate artificial data sets, that most closely reflect the
complexity of our sequenced sample set, including the spread in events, as well as
the genomic footprints (size)/lengths of the CDS of all the different genes within
the genome. We generated 109,000 artificial data sets, after which we created
histograms to assess the null distributions for all genes, as well as the likelihood
of finding combinations of recurrent events. The chance of finding any combina-
tion of three ormore genes affected in five ormore patients within our data set was
0.000211. Of note, this is a conservative estimation, as our real data set also
included four frequently affected genes in the MYCN amplicon. The chance of
affecting seven genes in five ormore patients ismuch lower than 1025. In addition,
the chances of finding ATRX, ODZ3 or PTPRD in five or more patients was
,1025, 6.423 1025 and 0.00534, respectively.
Statistical analysis for Rac/Rho GEF/GAP specificity. To ascertain whether the
ratio of mutations/structural variations in Rac-specific GEFs and Rho-specific
GAPs was significantly different from expectance, we performed Fisher’s exact
test on the number of mutations in GAP and GEF with specificity for only Rac or
Rho in our data set (one-sided Fisher’s exact test, P5 0.0007). We also pooled
events in Rac-specific GEFs and Rho-specific GAPs together and tested whether
they possessed more events than the pool of Rac-specific GAPs and Rho-specific
GEFs (one-sided Fisher’s exact test, P5 0.026).
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